Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Glass

Showing results (581-590 of 667) with videos related to

Pageof 67
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongationJ J Cook, G R Sitko, M A Holahan, et al.
Circulation|August 5, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injuryJ J Cook, J D Glass, G R Sitko, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitorsG D Hartman, M E Duggan, W F Hoffman, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
pTDP-43 levels correlate with cell type specific molecular alterations in the prefrontal cortex of <i>C9orf72</i> ALS/FTD patientsHsiao-Lin V Wang, Jian-Feng Xiang, Chenyang Yuan, et al.
Annals of Clinical and Translational Neurology|December 26, 2014
Analysis of graft survival in a trial of stem cell transplant in ALSTezeta Tadesse, Marla Gearing, David Senitzer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2025
pTDP-43 levels correlate with cell type-specific molecular alterations in the prefrontal cortex of <i>C9orf72</i> ALS/FTD patientsHsiao-Lin V Wang, Jian-Feng Xiang, Chenyang Yuan, et al.
Plos One|March 23, 2010
Dopamine neuron stimulating actions of a GDNF propeptideLuke H Bradley, Josh Fuqua, April Richardson, et al.
Science Advances|October 22, 2020
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's diseaseLenora Higginbotham, Lingyan Ping, Eric B Dammer, et al.
Molecular Neurodegeneration|October 26, 2017
Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patientsCsaba Konrad, Hibiki Kawamata, Kirsten G Bredvik, et al.
Cell Reports|March 20, 2026
Subtyping based on hippocampal cryptic exon burden reveals proteome-wide changes associated with TDP-43 and Alzheimer's disease pathologyAdam N Trautwig, Anantharaman Shantaraman, Mingee Chung, et al.
Pageof 67

Showing results (581-590 of 667) with videos related to

Sort By:
Pageof 67
The Journal of Pharmacology and Experimental Therapeutics|May 1, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongationJ J Cook, G R Sitko, M A Holahan, et al.
Circulation|August 5, 1997
Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injuryJ J Cook, J D Glass, G R Sitko, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitorsG D Hartman, M E Duggan, W F Hoffman, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
pTDP-43 levels correlate with cell type specific molecular alterations in the prefrontal cortex of <i>C9orf72</i> ALS/FTD patientsHsiao-Lin V Wang, Jian-Feng Xiang, Chenyang Yuan, et al.
Annals of Clinical and Translational Neurology|December 26, 2014
Analysis of graft survival in a trial of stem cell transplant in ALSTezeta Tadesse, Marla Gearing, David Senitzer, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 25, 2025
pTDP-43 levels correlate with cell type-specific molecular alterations in the prefrontal cortex of <i>C9orf72</i> ALS/FTD patientsHsiao-Lin V Wang, Jian-Feng Xiang, Chenyang Yuan, et al.
Plos One|March 23, 2010
Dopamine neuron stimulating actions of a GDNF propeptideLuke H Bradley, Josh Fuqua, April Richardson, et al.
Science Advances|October 22, 2020
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's diseaseLenora Higginbotham, Lingyan Ping, Eric B Dammer, et al.
Molecular Neurodegeneration|October 26, 2017
Fibroblast bioenergetics to classify amyotrophic lateral sclerosis patientsCsaba Konrad, Hibiki Kawamata, Kirsten G Bredvik, et al.
Cell Reports|March 20, 2026
Subtyping based on hippocampal cryptic exon burden reveals proteome-wide changes associated with TDP-43 and Alzheimer's disease pathologyAdam N Trautwig, Anantharaman Shantaraman, Mingee Chung, et al.
Pageof 67